Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983617 | 0.87 | PLA2G4B (0.57) | POLBL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL31752958 | 0.85 | PARP10 (0.67) | MAPTLMNAPOLBNPSR1MAOB | |
| SCHEMBL2989820 | 0.84 | MAPT (0.60) | MAPTLMNANPSR1L3MBTL1GAA | |
| SCHEMBL23818333 | 0.83 | NPC1 (0.55) | MAPTLMNAPOLBNPSR1L3MBTL1 | |
| SCHEMBL13958531 | 0.81 | ALDH1A1 (0.59) | MAPTLMNAPOLBNPSR1L3MBTL1 | |
| SCHEMBL17400969 | 0.80 | NQO1 (0.61) | MAPTRAB9AALDH1A1PARP10 | |
| SCHEMBL166144 | 0.80 | L3MBTL1 (0.70) | MAPTLMNAPOLBNPSR1L3MBTL1 | |
| SCHEMBL3010302 | 0.79 | MAPT (0.73) | MAPTLMNAPOLBNPSR1L3MBTL1 | |
| SCHEMBL16519363 | 0.78 | NQO1 (0.46) | MAPTPOLBMAOBHPGDRAB9A | |
| SCHEMBL13225087 | 0.78 | MAPT (0.67) | MAPTLMNAPOLBNPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | MAPT 2589/4885LMNA 1575/4885POLB 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.